MAS1 and Hepatic steatosis: These results are consistent with the conclusions obtained in HFD-fed mice treated with angiotensin receptor antagonists (angiotensin receptor blockers), which alleviate hepatic steatosis by activating ACE2/A1–7/MAS axis (36).